Eric Schmidt
Stock Analyst at Cantor Fitzgerald
(0.36)
# 4,019
Out of 4,732 analysts
38
Total ratings
15.38%
Success rate
-28.49%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eric Schmidt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INCY Incyte | Reiterates: Neutral | n/a | $71.93 | - | 6 | Jan 10, 2025 | |
| AGIO Agios Pharmaceuticals | Reiterates: Overweight | n/a | $32.42 | - | 4 | Dec 18, 2024 | |
| TNGX Tango Therapeutics | Reiterates: Overweight | n/a | $2.85 | - | 3 | Dec 5, 2024 | |
| ALMS Alumis | Reiterates: Overweight | n/a | $7.66 | - | 3 | Nov 14, 2024 | |
| BCAX Bicara Therapeutics | Initiates: Overweight | n/a | $12.11 | - | 1 | Oct 8, 2024 | |
| RNA Avidity Biosciences | Reiterates: Overweight | $96 | $28.92 | +231.95% | 4 | Sep 18, 2024 | |
| BLUE bluebird bio | Reiterates: Neutral | n/a | $8.35 | - | 2 | Sep 16, 2024 | |
| IMTX Immatics | Reiterates: Overweight | n/a | $5.35 | - | 3 | Sep 9, 2024 | |
| IMCR Immunocore Holdings | Reiterates: Overweight | n/a | $29.02 | - | 2 | Sep 9, 2024 | |
| BIIB Biogen | Reiterates: Overweight | $292 | $140.55 | +107.76% | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $40.53 | - | 3 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | n/a | $1.83 | - | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $370 | $422.00 | -12.32% | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.22 | - | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $0.74 | - | 1 | May 30, 2017 |
Incyte
Jan 10, 2025
Reiterates: Neutral
Price Target: n/a
Current: $71.93
Upside: -
Agios Pharmaceuticals
Dec 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $32.42
Upside: -
Tango Therapeutics
Dec 5, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.85
Upside: -
Alumis
Nov 14, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.66
Upside: -
Bicara Therapeutics
Oct 8, 2024
Initiates: Overweight
Price Target: n/a
Current: $12.11
Upside: -
Avidity Biosciences
Sep 18, 2024
Reiterates: Overweight
Price Target: $96
Current: $28.92
Upside: +231.95%
bluebird bio
Sep 16, 2024
Reiterates: Neutral
Price Target: n/a
Current: $8.35
Upside: -
Immatics
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.35
Upside: -
Immunocore Holdings
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $29.02
Upside: -
Biogen
Sep 9, 2024
Reiterates: Overweight
Price Target: $292
Current: $140.55
Upside: +107.76%
Aug 8, 2024
Reiterates: Neutral
Price Target: n/a
Current: $40.53
Upside: -
May 30, 2024
Initiates: Overweight
Price Target: n/a
Current: $1.83
Upside: -
Oct 17, 2023
Reiterates: Overweight
Price Target: $370
Current: $422.00
Upside: -12.32%
Oct 17, 2023
Downgrades: Neutral
Price Target: n/a
Current: $1.22
Upside: -
May 30, 2017
Initiates: Outperform
Price Target: n/a
Current: $0.74
Upside: -